Yliopiston Apteekki

University Pharmacy is owned by the University of Helsinki. In addition to the main pharmacy located in Helsinki, University Pharmacy has 16 branch pharmacies throughout Finland. Through its operations, University Pharmacy supports both research and education, and is the most significant employer of pharmaceutical personnel in Finland.

Related News

DIGITAL & DOCUMENTATION TRANSFORMATION KEY TO PHARMA, MANUFACTURING AND ENERGY SURVIVAL AMIDST COVID-19

Sdcexec | April 28, 2020

news image

Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...

Read More

BUSINESS INSIGHTS

ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA HAVE SIGNED A COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB)APAMISTAMAB)

Actinium Pharmaceuticals, Inc. | April 13, 2022

news image

Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option. "Immedica has est...

Read More

PFIZER CONTINUES RECALLS OF MENOPAUSE DRUG DUAVEE ON FAULTY PACKAGING CONCERNS

Fiercepharma | June 09, 2020

news image

Consumers are on edge as the COVID-19 pandemic casts doubts on the quality of drugs reaching shelves around the world. On U.S. shores, experts say those issues are warranted—and a wave of Pfizer recalls for menopause drug Duavee won't help build confidence. Pfizer voluntarily recalled two batches of Duavee––marketed as Duavive abroad––from U.K. shelves after identifying faulty packaging that may have reduced the drug's efficacy, the U.K.'s Medicines and ...

Read More

BUSINESS INSIGHTS

NEW INTERACTIVE APP FROM RXPERIUS SET TO PROVIDE PHARMA INDUSTRY WITH VITAL PATIENT EXPERIENCE INSIGHTS

rXperius | February 16, 2022

news image

Patients can now provide pharmaceutical manufacturers with real-time feedback on prescription medicines they are taking following the launch of a new app by rXperius, a Raleigh, NC-based company that specializes in the design of innovative technology platforms. The MedXer app, which can be downloaded from the Apple and Google app stores, is the first prescription survey app that allows patients to give feedback on their medications in real time, and over time. MedXer pays patients...

Read More
news image

DIGITAL & DOCUMENTATION TRANSFORMATION KEY TO PHARMA, MANUFACTURING AND ENERGY SURVIVAL AMIDST COVID-19

Sdcexec | April 28, 2020

Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...

Read More
news image

BUSINESS INSIGHTS

ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA HAVE SIGNED A COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB)APAMISTAMAB)

Actinium Pharmaceuticals, Inc. | April 13, 2022

Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option. "Immedica has est...

Read More
news image

PFIZER CONTINUES RECALLS OF MENOPAUSE DRUG DUAVEE ON FAULTY PACKAGING CONCERNS

Fiercepharma | June 09, 2020

Consumers are on edge as the COVID-19 pandemic casts doubts on the quality of drugs reaching shelves around the world. On U.S. shores, experts say those issues are warranted—and a wave of Pfizer recalls for menopause drug Duavee won't help build confidence. Pfizer voluntarily recalled two batches of Duavee––marketed as Duavive abroad––from U.K. shelves after identifying faulty packaging that may have reduced the drug's efficacy, the U.K.'s Medicines and ...

Read More
news image

BUSINESS INSIGHTS

NEW INTERACTIVE APP FROM RXPERIUS SET TO PROVIDE PHARMA INDUSTRY WITH VITAL PATIENT EXPERIENCE INSIGHTS

rXperius | February 16, 2022

Patients can now provide pharmaceutical manufacturers with real-time feedback on prescription medicines they are taking following the launch of a new app by rXperius, a Raleigh, NC-based company that specializes in the design of innovative technology platforms. The MedXer app, which can be downloaded from the Apple and Google app stores, is the first prescription survey app that allows patients to give feedback on their medications in real time, and over time. MedXer pays patients...

Read More